This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41409-024-02401-4/MediaObjects/41409_2024_2401_Fig1_HTML.png)
References
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. https://doi.org/10.1056/NEJMoa1804980.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447.
Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:7505. https://doi.org/10.1200/JCO.2018.36.15_suppl.7505. 15_suppl
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet (Lond, Engl). 2022;399:2294–308. https://doi.org/10.1016/s0140-6736(22)00662-6
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54. https://doi.org/10.1056/NEJMoa2116133.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32–9. https://doi.org/10.1182/bloodadvances.2022008525
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145–54. https://doi.org/10.1038/s41591-022-01969-y.
Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349–58. https://doi.org/10.1182/blood.2021015209
Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transpl Cell Ther. 2022;28:669–76. https://doi.org/10.1016/j.jtct.2022.07.011.
Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021;14:140. https://doi.org/10.1186/s13045-021-01144-9.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transpl Cell Ther. 2024;30:77.e71–77.e15. https://doi.org/10.1016/j.jtct.2023.10.017.
Author information
Authors and Affiliations
Contributions
UN was PI of the study, conceptualized study design the survey and data collection. UN provided the study synopsis and the survey form. JEM performed the statistical analysis. MD, CS, LG, IYA, RR, EF, LLC, EN, EG, FS, WB, EMWD, SM, CA, FS were the PIs of the centers mainly involved in the survey and performed data-collection at the center level. JDH performed data management, implemented the online SurveyMonkey tool, and coordinated the study at the EBMT level. CC, JK, AR and FM supervised the study, interpreted the data analysis and gave important intellectual inputs. CC, JK, AR edited the manuscript. FM wrote the manuscript and designed the figures. CTIWP data management team takes the responsibility for the integrity and accuracy of the data presented. All authors reviewed and approved the final version of this manuscript.
Corresponding author
Ethics declarations
Competing interests
FS: travel Support from Janssen, medac; honoraria from medac, GWT, Abbvie, Servier, Pierre Fabre; research funding from medac, Servier. CA: institutional consulting fees through CHUV from Gilead, Janssen, Celgene/ BMS; institutional sponsored travel through CHUV from Gilead; institutional licensing fees and royalties through previous institution Baylor College of Medicine from Immatics; patents and provisional patent applications in the field of engineered T cell therapies. FS: institutional consulting fees from BMS/Celgene, Incyte, Kite/Gilead; speaker fees from Kite/Gilead, Incyte; travel support from Kite/Gilead, Novartis, AstraZeneca, Neovii, Janssen; research funding from Kite/Gilead, Novartis, BMS/Celgene. CC: Institutional / personal honoraria and travel funding from BMS, Janssen, Jazz, Kite / Gilead, Miltenyi biotec, Novartis. JK: research support from Novartis, Miltenyi Biotech, Gadeta. Florent Malard: honoraria from BMS, Therakos/Mallinckrodt, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, AstraZeneca and MSD, all outside the submitted work. The other authors declare no competing financial interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Novak, U., Mooyaart, J.E., Daskalakis, M. et al. Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02401-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02401-4